MVA-HCV
AssetVaccineAlso MVA-HCV (Immunotherapy)
Modified vaccinia Ankara viral vector expressing hepatitis C virus antigens to elicit immune response.
- Stage
- Phase 1
- Modality
- Vaccine
- Target
- Inflammation
- Indications
- 1
- Trials
- 114
- Developers
- 1
Indications
1Chronic hepatitis c
Phase 1COMPLETEDNCT00529321clinicaltrials.gov7 Oct 2026
- Targets and what it contains2
- Owner and partners1
- Trials114
- Evidence for its targets2
- Competitors1
- Signals12
Every asset’s record: target, stage, trials and the evidence behind it.
See ProUpdated 7 Oct 2026 · 2 sources